FamiCord AG, Europe's leading cell bank and the third largest worldwide, announced that its CDMO brand Bramble Bio has entered into a manufacturing agreement with Swedish clinical-stage biotechnology company VERIGRAFT AB. The agreement covers the transfer and establishment of the manufacturing process for VERIGRAFT's lead product candidate P-TEV, a personalized tissue-engineered vein, as well as support for sourcing and qualifying donated human vein tissue used as starting material. The collaboration supports preparations for the pivotal Phase II/III trial TECVI-2 and further expands FamiCord's CDMO activities.
Technology-transfer activities to Bramble Bio's GMP site in Warsaw, Poland, will begin immediately. The company will perform the process transfer, manufacturing preparation, and related GMP activities required to supply the multi-country clinical trial. The collaboration is expected to run for approximately 18 months and has an estimated contract value in the low single-digit millions of euros, depending on the progress of the clinical program, patient recruitment, and associated manufacturing requirements. This agreement adds a pivotal Phase II/III program to FamiCord's CDMO portfolio, signaling a strategic move into late-stage clinical manufacturing and strengthening its position in the advanced therapy medicinal products (ATMP) market.
"The agreement with VERIGRAFT marks another concrete step in the development of our CDMO activities," said Jakub Baran, CEO of FamiCord AG. "Supporting a pivotal Phase II/III program requires close technical cooperation, rigorous process control, and reliable cross-border logistics. The project broadens our portfolio with a late-stage clinical program and underlines the capabilities we have built at our Warsaw site."
TECVI-2 is a randomized, controlled, open-label Phase II/III pivotal clinical trial designed to assess the efficacy of P-TEV in a larger patient population. Clinical sites are planned in Spain, Poland, and the Netherlands. The trial is currently authorized in Spain under the EU Clinical Trials Regulation, and approval in Poland and the Netherlands is expected in Q4 2026. TECVI-2 is expected to start in Q1 2027 and will evaluate P-TEV as a potentially curative treatment for patients suffering from severe chronic venous insufficiency (CVI). The trial is intended to support future marketing authorization applications in Europe and the United States.
"Establishing a robust and scalable manufacturing capability is fundamental to the successful delivery of TECVI-2 and to the future development of P-TEV. Bramble Bio combines specialist ATMP manufacturing expertise with the flexibility and commitment required for a complex, personalized therapy," said Petter Bjorquist, CEO of VERIGRAFT. "We look forward to working closely with their team as we transfer our process and prepare to supply this important multi-country clinical trial."
P-TEV is a personalized, fully biological tissue-engineered vein with a functioning valve, being developed for patients with severe CVI. The therapy starts with donated venous tissue, which is decellularized to remove donor cells while preserving the native tissue and valve structure. The resulting matrix is then reconditioned with the patient's own blood to create a personalized graft, designed to replace a diseased vein segment containing a non-functioning valve and restore venous function without requiring immunosuppressive treatment.
Simon Boa, Managing Director of Bramble Bio, sees the project as a sweet spot deal for the company. "Technology transfer and clinical manufacturing for a personalized tissue-engineered product require close technical collaboration, rigorous process control, and carefully coordinated logistics. These are core areas of expertise for our CDMO team."
Bramble Bio supports biotechnology and pharmaceutical companies with technology transfer, process development and optimization, GMP manufacturing, cellular starting-material sourcing, analytical services, and international logistics. In addition to Warsaw, Bramble Bio operates a GMP site in Cantanhede, Portugal. Further information on FamiCord and its subsidiaries can be found at www.famicord.com. Further information on VERIGRAFT can be found at www.verigraft.com.
The agreement matters because it demonstrates FamiCord's ability to attract late-stage clinical programs, validating its CDMO strategy and infrastructure. For VERIGRAFT, securing a reliable manufacturing partner is critical to advancing P-TEV through pivotal trials and eventual commercialization. The collaboration also highlights the growing importance of specialized manufacturing for personalized therapies, which require complex logistics and regulatory compliance. As the ATMP market expands, FamiCord's experience with human biological materials and GMP manufacturing positions it as a key player in the contract development and manufacturing space. The deal's initial value in the low single-digit millions of euros, with potential for extension, provides near-term revenue and opens doors to future contracts, reinforcing FamiCord's dual focus on stable cell banking and high-growth CDMO services.
